Please enable JavaScript in your browser. 
Skip to main content
Drug Information Portal National Library of Medicine
Home
 
       Home    Substance
     
Result
PropertyValue
Drug Name: Lenvatinib [USAN:INN] View Structure
Description: A protein kinase inhibitor.

NCI: A synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. Lenvatinib mesylate blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis. Check for active clinical trials or closed clinical trials using this agent. /Mesylate/ (NCI Thesaurus) 
Categories:



 
 
Site Map, Contact Us, Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services
Freedom of Information Act
Drug Information Portal Mobile Site
Last updated: Aug 2017
USA.gov